Health Canada has amended the Prescription Drug List (PDL) to require a prescription for all sleep-related use of melatonin in children and adolescents under 18 years of age. The amendment, published June 2, 2026, broadens an earlier qualifier that had been in place since September 2025 and was limited to melatonin used for insomnia in children with Autism Spectrum Disorder or Smith-Magenis syndrome.
Under the updated listing, melatonin intended for any sleep-related indication in children and adolescents under 18 is now classified as a prescription drug, regardless of the underlying condition. The amendment changes how these products are regulated under the Food and Drugs Act and Food and Drug Regulations.
Any drug containing melatonin that is marketed for sleep-related use in the pediatric population must now be authorized and sold as a prescription drug. Existing licensed Natural Health Product (NHPs) containing melatonin are not affected, as all currently authorized melatonin NHPs are indicated for adult use only.
How the PDL Qualifier Changed
The September 2025 qualifier was narrow by design. It applied to melatonin only used for the treatment of insomnia in children aged 2 to under 18 with ASD or Smith-Magenis syndrome. The June 2026 amendment replaces that diagnosis-specific qualifier with broader language covering melatonin or its salts, when sold for sleep-related use in children and adolescents under 18 years of age.
This represents a significant expansion in regulatory scope. Rather than being limited to specific medical conditions, the prescription requirement now applies to all pediatric sleep-related uses of melatonin.
Health Canada concluded that physician oversight is appropriate for this age group to ensure that potential underlying causes of sleep disturbances are evaluated, caregivers receive guidance on non-pharmacological approaches such as sleep hygiene before medication is considered, and dosing is determined based on the individual patient’s needs.
The NHP Pathway for Pediatric Melatonin Was Already Closed
An important point for NHP product licence holders to understand: this amendment formalizes a restriction that the NHP framework had already effectively put in place. The current NNHPD melatonin monographs, both oral and sublingual, both updated in 2024, limit authorized uses to adults. As a result, there are no authorized NHPs containing melatonin with pediatric indications in Canada, and there was no NHP pathway available for companies seeking to add pediatric claims to melatonin products prior to this amendment.
The only authorized product for pediatric melatonin use in Canada is Slenyto, a prolonged-release prescription drug authorized for treating insomnia in children aged 2 to under 18 with ASD or Smith-Magenis syndrome. Slenyto remains within the scope of the amended Prescription Drug List (PDL) qualifier.
Companies wishing to market melatonin for any sleep-related use in children or adolescents under 18 years of age must pursue authorization as a prescription drug and obtain a Drug Identification Number (DIN) through Health Canada’s Pharmaceutical Drugs Directorate under the Food and Drug Regulations.
Transition Timeline and Compliance Expectations
Health Canada has indicated a transition period will be provided to allow affected licence holders to adjust their product registrations, labelling, and distribution arrangements. Details of the transition, including applicable timelines and compliance dates, are expected to be confirmed in the final implementation notice.
While companies should await Health Canada’s final direction on the transition process, they need not delay internal planning. Regulatory changes of this nature commonly include a defined transition period to facilitate compliance before the new requirements are fully enforced.
Affected companies should review their product labelling, marketing materials, and commercialization strategies to ensure they remain consistent with authorized adult-only indications. Companies seeking to market melatonin for sleep-related use in children or adolescents under 18 years of age must pursue authorization as a prescription drug by obtaining a Drug Identification Number (DIN) under the Food and Drug Regulations. Each regulatory pathway involves different evidentiary requirements, timelines, costs, and commercial considerations. Therefore, the appropriate strategy will depend on the company’s product portfolio and market objectives.
What This Means for Your Business
1. If Your Melatonin Product Is Adult-Only
For most NHP licence holders, this amendment has no immediate operational impact, provided their melatonin products are accurately labelled and positioned for adult use only. The critical question is whether any current product label, dosing table, or marketing material contains language that could be read as directing melatonin use toward children.
This includes e-commerce listings, social media content, and retailer product descriptions. Even implicit pediatric positioning, such as child-friendly product formats or imagery, could draw regulatory scrutiny under the new framework. Conducting a comprehensive review of labelling and marketing materials is a practical first step to ensure adult-only positioning is clear and consistent across all channels.
2. If You Were Exploring a Pediatric Melatonin Product
Companies that have been assessing whether a pediatric melatonin NHP could be viable now have a definitive answer: that pathway is closed. Any product seeking to make sleep-related claims for children or adolescents under 18 must be authorized as a prescription drug.
3. Pursuing the Prescription Drug Pathway
Developing a prescription melatonin product is a substantially different regulatory undertaking than obtaining an NHP licence. Depending on the product and supporting evidence, authorization may require a New Drug Submission (NDS) or an Abbreviated New Drug Submission (ANDS), together with compliance with applicable pharmaceutical quality, safety, and efficacy requirements, as well as post-market requirements, under the Food and Drug Regulations. Companies considering this pathway should assess the regulatory, evidentiary, commercial, and lifecycle implications early in product development.
Frequently Asked Questions
Does this amendment affect adult melatonin NHPs currently on the market?
No. The amended Prescription Drug List (PDL) qualifier applies only to melatonin sold for sleep-related use in children and adolescents under 18 years of age. Melatonin NHPs authorized for adult use only are not affected by the June 2026 amendment and continue to be regulated under the Natural Health Products Regulations. Licence holders should nevertheless confirm that their product labelling, dosing instructions, advertising, and other promotional materials are consistent with their authorized adult-only indications.
Can a company remove pediatric claims from its melatonin product to maintain NHP status?
No. Health Canada’s current NHP framework does not provide a pathway for melatonin products with pediatric sleep-related indications. The June 2026 amendment reinforces that products intended for sleep-related use in children or adolescents under 18 fall within the prescription drug framework. Companies wishing to maintain NHP status should ensure their products are authorized, labelled, and marketed exclusively for adult use.
What must a company do if it wants to market melatonin for pediatric sleep use in Canada?
Any company wishing to market melatonin for sleep-related use in children or adolescents under 18 must seek authorization under the Food and Drug Regulations through Health Canada’s Pharmaceutical Drugs Directorate. This involves a drug submission process with pharmaceutical-grade evidence requirements, which is a materially different pathway from the NHP licensing process.
Key Takeaways
- Health Canada’s June 2, 2026, PDL amendment requires a prescription for all Melatonin sleep-related use in children and adolescents under 18, replacing the narrower 2025 qualifier that applied only to certain pediatric indications.
- The amendment came into force on June 2, 2026. The published Health Canada notice does not provide for a transition period.
- Existing adult-use melatonin NHPs are not affected, provided their labelling and marketing contain no pediatric indications.
- The NHP pathway for pediatric melatonin claims was already effectively closed under the current NNHPD monographs; this amendment makes that restriction explicit in the PDL.
- Companies wishing to market melatonin for pediatric sleep use must pursue a DIN through Health Canada’s Pharmaceutical Drugs Directorate under the Food and Drug Regulations.
- All melatonin product labels, NHP licence conditions, and consumer-facing materials should be audited to confirm adult-only positioning is clear and consistent.
Preparing for the Change Ahead
For companies with melatonin products in their Canadian portfolio, the immediate priority right now is clarity on positioning. A thorough review of all product labels, NHP licence conditions, and consumer-facing materials can help ensure they remain consistent with authorized adult-only indications and fall outside the scope of the amended Prescription Drug List (PDL) qualifier.
Companies considering the development of melatonin products for sleep-related use in children or adolescents under 18 should plan early for the prescription drug authorization process. Obtaining a Drug Identification Number (DIN) under the Food and Drug Regulations involves substantially different evidentiary, quality, and regulatory requirements than the natural health product framework.
Quality Smart Solutions helps companies navigate Canada’s natural health product, non-prescription drug, and prescription drug regulatory frameworks. Whether you are reviewing an existing product portfolio or evaluating a new market opportunity, our regulatory experts can help you determine the appropriate pathway and develop a practical compliance strategy.
To learn more about NHP licensing, DIN application, and regulatory compliance services, or to discuss how this amendment may affect your products, contact Quality Smart Solutions.
